<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2021.112007</article-id><article-id pub-id-type="publisher-id">WJCR-41823</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20210200000_37789486.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胃癌组织中EBV、Hp感染及其与HER2、P53、Ki-67蛋白表达的相关性研究
  EBV and HP Infections in Gastric Cancer Tissues and Their Correlation with HER2, P53, Ki-67 Gene Expression
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>江</surname><given-names>杨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>艳芳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>雪纯</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邱</surname><given-names>荣元</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>婕</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>毛</surname><given-names>敏</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>崇梅</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南华大学研究生院，湖南 衡阳</addr-line></aff><aff id="aff4"><addr-line>湖南省岳阳市二人民医院消化内科，湖南 岳阳</addr-line></aff><aff id="aff3"><addr-line>湖南省岳阳市二人民医院病理科，湖南 岳阳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>48</fpage><lpage>58</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：评价EB病毒、幽门螺杆菌感染与胃癌组织中表皮生长HER2、P53、Ki-67表达的相关性，初步探讨两者感染在胃癌发生发展的相关作用。方法：收集我院行胃癌根治手术病例的组织蜡块共78例，采用原位杂交方法检测胃癌组织中EBV感染情况，利用免疫组织化学方法检测胃癌组织中Hp感染状态以及HER2、P53、Ki-67等蛋白表达情况。结果：EBV感染阳性率为12.8% (10/78)，Hp阳性率为57.7% (45/78)，EBV、Hp两者感染不存在一致性；胃癌组织中EBV、Hp感染分别与性别、年龄、淋巴结有无转移、胃腺癌分化程度、浸润深度、临床分期无显著差异；HER2、P53、Ki-67等蛋白表达在胃癌组织中与性别、年龄、淋巴结有无转移、腺癌分化程度、浸润深度、临床分期无显著差异；P53、Ki-67蛋白表达与Hp感染有显著性差异，P53、Ki-67蛋白表达与Hp感染存在正相关关系，Hp阳性组与Hp阴性组HER2蛋白表达无显著性差异；EBV阳性或Hp阳性组与两者联合感染组中P53、Ki-67蛋白表达差异无统计学意义。结论：Hp感染组与非感染组胃癌组织中P53、Ki-67表达存在显著差异，且Hp感染与P53、Ki-67表达呈正相关，胃癌组织中Hp感染可能促进上述蛋白表达；胃癌组织中EBV或Hp感染和EBV、Hp联合感染分别对HER2、P53、Ki-67蛋白表达无增强作用，两者之间无相关性，EBV、Hp可能是胃癌发生发展中的两个独立因素。
    Objective: This study is aimed to evaluate the correlation between Epstein-Barr virus, Helicobacter pylori infection and the expression of human epidermal growth factor receptor-2, P53 and Ki-67 in Gastric Cancer tissues, which is helpful to determine the correlation between those two pathogen and gastric cancer. Methods: A total of 78 cases of tissue wax blocks for radical gastric cancer surgery in our Hospital were collected. In situ hybridization was used to detect EBV infection in gastric cancer tissues, and immunohistochemical methods were used to detect the status of HP infection and the expression of HER2, P53, Ki-67 and other proteins in gastric cancer tissues. Results: The positive rate of EBV infection was 12.8% (10/78) and the positive rate of HP was 57.7% (45/78). There is no consistency between the two infections. There were no significant differences between EBV and HP infections in gastric cancer tissues, including gender, age, lymph node metastasis, gastric adenocarcinoma differentiation, depth of invasion, and clinical stage. The expression of HER2, P53, Ki-67 and other proteins in gastric cancer tissues were not significantly different from sex, age, lymph node metastasis, adenocarcinoma differentiation, invasion depth, and clinical stage. The expressions of P53 and Ki-67 proteins were significantly different from Hp infection. There was a positive correlation between the expression of P53 and Ki-67 and Hp infection. There was no significant difference in HER2 protein expression between Hp-positive group and Hp-negative group. There was no significant difference in the expression of P53 and Ki-67 protein between EBV positive or HP positive group and EBV combined HP infection group. Conclusion: There were significant differences in the expression of P53 and Ki-67 in gastric cancer tissues between the HP infection group and the non-infection group, and Hp infection was positively correlated with the expression of P53 and Ki-67. Hp infection in gastric cancer tissues may promote the above protein expression. EBV or HP infection and EBV and Hp infection in gastric cancer tissues have no effect on the enhancement of P53 and Ki-67 protein expression, respectively, and there is no correlation between them. EBV and Hp may be two independent factors in the development of gastric cancer. 
  
 
</p></abstract><kwd-group><kwd>胃癌，EB病毒，幽门螺旋杆菌，表皮生长因子受体，P53，Ki-67, Gastric Cancer</kwd><kwd> Epstein-Barr Virus</kwd><kwd> Helicobacter Pylori</kwd><kwd> Epidermal Growth Factor Receptor</kwd><kwd> P53</kwd><kwd> Ki-67</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：评价EB病毒、幽门螺杆菌感染与胃癌组织中表皮生长HER2、P53、Ki-67表达的相关性，初步探讨两者感染在胃癌发生发展的相关作用。方法：收集我院行胃癌根治手术病例的组织蜡块共78例，采用原位杂交方法检测胃癌组织中EBV感染情况，利用免疫组织化学方法检测胃癌组织中Hp感染状态以及HER2、P53、Ki-67等蛋白表达情况。结果：EBV感染阳性率为12.8% (10/78)，Hp阳性率为57.7% (45/78)，EBV、Hp两者感染不存在一致性；胃癌组织中EBV、Hp感染分别与性别、年龄、淋巴结有无转移、胃腺癌分化程度、浸润深度、临床分期无显著差异；HER2、P53、Ki-67等蛋白表达在胃癌组织中与性别、年龄、淋巴结有无转移、腺癌分化程度、浸润深度、临床分期无显著差异；P53、Ki-67蛋白表达与Hp感染有显著性差异，P53、Ki-67蛋白表达与Hp感染存在正相关关系，Hp阳性组与Hp阴性组HER2蛋白表达无显著性差异；EBV阳性或Hp阳性组与两者联合感染组中P53、Ki-67蛋白表达差异无统计学意义。结论：Hp感染组与非感染组胃癌组织中P53、Ki-67表达存在显著差异，且Hp感染与P53、Ki-67表达呈正相关，胃癌组织中Hp感染可能促进上述蛋白表达；胃癌组织中EBV或Hp感染和EBV、Hp联合感染分别对HER2、P53、Ki-67蛋白表达无增强作用，两者之间无相关性，EBV、Hp可能是胃癌发生发展中的两个独立因素。</p></sec><sec id="s2"><title>关键词</title><p>胃癌，EB病毒，幽门螺旋杆菌，表皮生长因子受体，P53，Ki-67</p></sec><sec id="s3"><title>EBV and HP Infections in Gastric Cancer Tissues and Their Correlation with HER2, P53, Ki-67 Gene Expression</title><p>Yang Jiang<sup>1</sup>, Yanfang Tang<sup>1</sup>, Xuechun Zhang<sup>2</sup>, Rongyuan Qiu<sup>3</sup>, Jie Wang<sup>2</sup>, Min Mao<sup>2</sup>, Chongmei Liu<sup>2</sup></p><p><sup>1</sup>Graduate School of University of South China, Hengyang Hunan</p><p><sup>2</sup>Department of Pathology, Yueyang Second People’s Hospital, Yueyang Hunan</p><p><sup>3</sup>Department of Gastroenterology, Yueyang Second People’s Hospital, Yueyang Hunan</p><p><img src="//html.hanspub.org/file/3-2150211x5_hanspub.png" /></p><p>Received: Mar. 28<sup>th</sup>, 2021; accepted: Apr. 18<sup>th</sup>, 2021; published: Apr. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/3-2150211x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: This study is aimed to evaluate the correlation between Epstein-Barr virus, Helicobacter pylori infection and the expression of human epidermal growth factor receptor-2, P53 and Ki-67 in Gastric Cancer tissues, which is helpful to determine the correlation between those two pathogen and gastric cancer. Methods: A total of 78 cases of tissue wax blocks for radical gastric cancer surgery in our Hospital were collected. In situ hybridization was used to detect EBV infection in gastric cancer tissues, and immunohistochemical methods were used to detect the status of HP infection and the expression of HER2, P53, Ki-67 and other proteins in gastric cancer tissues. Results: The positive rate of EBV infection was 12.8% (10/78) and the positive rate of HP was 57.7% (45/78). There is no consistency between the two infections. There were no significant differences between EBV and HP infections in gastric cancer tissues, including gender, age, lymph node metastasis, gastric adenocarcinoma differentiation, depth of invasion, and clinical stage. The expression of HER2, P53, Ki-67 and other proteins in gastric cancer tissues were not significantly different from sex, age, lymph node metastasis, adenocarcinoma differentiation, invasion depth, and clinical stage. The expressions of P53 and Ki-67 proteins were significantly different from Hp infection. There was a positive correlation between the expression of P53 and Ki-67 and Hp infection. There was no significant difference in HER2 protein expression between Hp-positive group and Hp-negative group. There was no significant difference in the expression of P53 and Ki-67 protein between EBV positive or HP positive group and EBV combined HP infection group. Conclusion: There were significant differences in the expression of P53 and Ki-67 in gastric cancer tissues between the HP infection group and the non-infection group, and Hp infection was positively correlated with the expression of P53 and Ki-67. Hp infection in gastric cancer tissues may promote the above protein expression. EBV or HP infection and EBV and Hp infection in gastric cancer tissues have no effect on the enhancement of P53 and Ki-67 protein expression, respectively, and there is no correlation between them. EBV and Hp may be two independent factors in the development of gastric cancer.</p><p>Keywords:Gastric Cancer, Epstein-Barr Virus, Helicobacter Pylori, Epidermal Growth Factor Receptor, P53, Ki-67</p><disp-formula id="hanspub.41823-formula29"><graphic xlink:href="//html.hanspub.org/file/3-2150211x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-2150211x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-2150211x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>胃癌是最常见及危害最大的恶性肿瘤之一，其发病率是所有恶性肿瘤中的第四位 [<xref ref-type="bibr" rid="hanspub.41823-ref1">1</xref>]。目前针对胃癌手术治疗仍是当今主流，辅以化疗、放疗、免疫治疗等综合治疗。但化疗、放疗治疗效果欠佳，且针对性弱、毒副作用大。因而，分子靶向治疗应运而生，它具有针对性强、毒副作用小的优点，主要是通过肿瘤细胞过度表达的分子作为治疗靶点，选择相应分子特异性阻断剂从而阻断肿瘤生长，而达到治疗目的，可控制肿瘤复发和转移 [<xref ref-type="bibr" rid="hanspub.41823-ref2">2</xref>]。胃癌的发生和发展是复杂、多阶段、多因素参与而成的，其中包括环境因素、饮食因素、遗传基因因素、Hp以及癌前病变等。近几年亦有学者提出胃癌组织中EB病毒感染与胃癌具有一定的相关性。Hp已被证实为胃癌发生发展中主要危险因素之一。目前已知Hp可致胃部产生炎症、破坏胃黏膜组织、影响胃酸产生，是大部分胃炎、胃十二指肠溃疡的病因，与胃黏膜相关B细胞淋巴瘤密切相关。且有多项研究证明，Hp感染与胃癌关系密切。HER2、P53、Ki-67均属于肿瘤相关蛋白。这些肿瘤蛋白由肿瘤细胞分泌产生，是肿瘤诊断、个体化精准治疗以及预测肿瘤病人的预后重要指标。目前胃癌组织中EBV感染联合Hp感染对胃癌组织中的相关蛋白表达的影响的研究，国内外有关文献报道较少，胃癌患者中EBV联合Hp感染与胃癌组织中HER2、P53、Ki-67的表达的相关性暂无统一结论。本研究为评价胃癌组织中Hp、EBV感染及联合感染与胃癌组织中HER2、P53、Ki-67表达的差异。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>收集2017年12月到2019年12月在我院行胃癌根治术病例石蜡组织块78例，其中男性58例，女性20例。年龄45~83岁，中位年龄为63岁，平均年龄为(62 &#177; 7.959)岁。其中有淋巴结转移44例、无淋巴结转移34例；高分化腺癌2例、中分化腺癌33例、低分化腺癌29例；浸润深度局限在黏膜层的2例、黏膜下层31例、肌层24例、浆膜层11例；临床分期为I期的24例、II期26例、III期19例、IV期19例。入选标准有：术后明确诊断为胃癌患者；术前未行抗Hp､抗EBV治疗患者；所有患者均未行术前辅助放化疗；所有入选患者临床资料齐全｡排除标准有：病理组织学证实为非胃癌患者；术前已行抗Hp､抗EBV治疗患者；术前行辅助放化疗；患者临床病史及诊疗资料不全者｡</p></sec><sec id="s6_2"><title>2.2. 实验方法</title><sec id="s6_2_1"><title>2.2.1. 免疫组织化学方法</title><p>免疫组织化学结果由两名经验丰富的高年资病理医师独立观察评估，每个标本选择5个10 &#215; 40倍随机视野下进行观察，每个视野计数100个细胞，计数阳性细胞比例｡以PBS溶液替代一抗作为空白对照，以已知的阳性切片标本作为阳性对照。</p><p>1) HER2阳性结果判读：HER2阳性着色在细胞膜上呈棕黄色颗粒，0 (阴性)：细胞未染色或≤10%的细胞的细胞膜有着色；1+ (弱阳性)： &gt; 10%有微弱/勉强可见的膜着色，或细胞只有部分膜着色。2+ (阳性)：&gt;10%肿瘤细胞有弱到中等完全或基地外侧膜着色；3+ (强阳性)：&gt;10%的肿瘤细胞有中等到强完全或基地外侧膜着色。</p><p>2) P53阳性结果判读：P53着色在细胞核内呈棕黄色颗粒，0 (阴性)：0%~24%细胞核着色；1+ (弱阳性)：25%~50%的细胞核着色；2+ (阳性)：51%~75%的细胞核着色。3+ (强阳性)：≥76%的细胞核着色。</p><p>3) Ki-67阳性结果判读：Ki-67着色在细胞核内呈棕黄色颗粒，0 (阴性)：0%~9%细胞核着色；1+ (弱阳性)：10%~24%的细胞核着色；2+ (阳性)：25%~49%的细胞核着色。3+ (强阳性)：≥50%的细胞核着色。</p><p>4) 胃癌组织中Hp免疫组织化学检测结果判读：以广州安必平医药科技股份有限公司提供的Helicobacter pylori抗体试剂盒说明书为准，即组织切片中Hp感染部位呈棕色/棕黄色染色、细胞核呈蓝色判读为阳性。</p></sec><sec id="s6_2_2"><title>2.2.2. EBER原位杂交方法</title><p>采用EBER原位杂交法，进行EB病毒检测。操作严格按照EBER试剂盒说明书进行，用已知阳性标本作阳性对照。全操作过程保持在25℃~28℃之间，相对湿度&gt;70%。结果判读：以北京中杉金桥生物技术有限公司提供的地高辛染色液说明书结果判读为准，细胞核中可见黄色至棕黄色颗粒判读为阳性。</p></sec></sec><sec id="s6_3"><title>2.3. 统计学分析</title><p>本实验研究所用数据分析和统计分析均采用IBM SPSS 26.0统计软件完成。并以P &lt; 0.05认为有统计学意义。计数资料采用卡方检验、Fisher确切概率法，两组独立样本采用非参数Mann-whitney U检验。组间等级资料采用Kruskal-Wallis H检验。相关性研究分类变量采用Spearman相关分析。一致性分析采用Kappa一致性分析。</p></sec><sec id="s6_4"><title>2.4. 伦理审查</title><p>本研究已通过南华大学附属岳阳市二医院伦理委员会审批，审批号：YYEYY-KY20190023。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 胃癌组织中EBV、Hp感染及蛋白表达情况与患者临床病理参数的关系</title><p>78例患者胃癌组织中EBV阳性率为12.8% (10/78)，Hp阳性率为57.7% (45/78)，HER2阳性率为24.4% (19/78)，P53阳性率为38.5% (30/78)，Ki-67阳性率为52.6% (41/78)，EBV、Hp感染情况、HER2、P53、Ki-67蛋白表达在患者年龄、性别、有无淋巴结转移、腺癌分化程度、浸润深度、临床分期均无明显差异(P &gt; 0.05)，见表1、表2。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The Relationships between EBV infection and clinical pathologic characteristics in Gastric Cancer Tissue</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >EBV阳性n(%)</th><th align="center" valign="middle" >EBV阴性n(%)</th><th align="center" valign="middle" >χ<sup>2</sup>值</th><th align="center" valign="middle"  colspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >&lt;60</td><td align="center" valign="middle" >2 (20.0)</td><td align="center" valign="middle" >31 (45.6)</td><td align="center" valign="middle"  rowspan="2"  >2.339</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.126</td></tr><tr><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >8 (80.0)</td><td align="center" valign="middle" >37 (54.4)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >8 (80.0)</td><td align="center" valign="middle" >50 (73.5)</td><td align="center" valign="middle"  rowspan="2"  >0.191</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.728</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >2 (20.0)</td><td align="center" valign="middle" >18 (26.5)</td></tr><tr><td align="center" valign="middle" >淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >3 (30.0)</td><td align="center" valign="middle" >41 (60.3)</td><td align="center" valign="middle"  rowspan="2"  >3.254</td><td align="center" valign="middle"  rowspan="2"  >0.093</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >7 (70.0)</td><td align="center" valign="middle" >27 (39.7)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >胃腺癌分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高分化</td><td align="center" valign="middle" >1 (12.5)</td><td align="center" valign="middle" >1 (1.8)</td><td align="center" valign="middle"  rowspan="3"  >2.742</td><td align="center" valign="middle"  rowspan="3"  >0.337</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中分化</td><td align="center" valign="middle" >4 (50.0)</td><td align="center" valign="middle" >29 (51.8)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >低分化</td><td align="center" valign="middle" >3 (37.5)</td><td align="center" valign="middle" >26 (46.2)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >浸润深度</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >黏膜层</td><td align="center" valign="middle" >3 (30.0)</td><td align="center" valign="middle" >9 (13.2)</td><td align="center" valign="middle"  rowspan="4"  >2.107</td><td align="center" valign="middle"  rowspan="4"  >0.591</td></tr><tr><td align="center" valign="middle" >黏膜下层</td><td align="center" valign="middle" >4 (40.0)</td><td align="center" valign="middle" >27 (39.7)</td></tr><tr><td align="center" valign="middle" >肌层</td><td align="center" valign="middle" >2 (20.0)</td><td align="center" valign="middle" >22 (32.4)</td></tr><tr><td align="center" valign="middle" >浆膜层</td><td align="center" valign="middle" >1 (10.0)</td><td align="center" valign="middle" >10 (14.7)</td></tr><tr><td align="center" valign="middle" >临床分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I期</td><td align="center" valign="middle" >2 (20.0)</td><td align="center" valign="middle" >22 (32.4)</td><td align="center" valign="middle"  rowspan="4"  >1.454</td><td align="center" valign="middle"  rowspan="4"  >0.791</td></tr><tr><td align="center" valign="middle" >II期</td><td align="center" valign="middle" >5 (50.0)</td><td align="center" valign="middle" >21 (30.9)</td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >2 (20.0)</td><td align="center" valign="middle" >17 (25.0)</td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >1 (10.0)</td><td align="center" valign="middle" >8 (11.8)</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 胃癌组织中EBV感染情况与临床病理参数关系</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The Relationships between HP infection and clinical pathologic characteristics in Gastric Cancer Tissue</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >Hp阳性n(%)</th><th align="center" valign="middle" >Hp阴性n(%)</th><th align="center" valign="middle" >χ<sup>2</sup>值</th><th align="center" valign="middle"  colspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >&lt;60</td><td align="center" valign="middle" >19 (42.2)</td><td align="center" valign="middle" >14 (42.4)</td><td align="center" valign="middle"  rowspan="2"  >0.000</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.986</td></tr><tr><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >26 (57.8)</td><td align="center" valign="middle" >19 (57.6)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >32 (71.1)</td><td align="center" valign="middle" >26 (78.8)</td><td align="center" valign="middle"  rowspan="2"  >0.588</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.601</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >13 (28.9)</td><td align="center" valign="middle" >7 (21.2)</td></tr><tr><td align="center" valign="middle" >淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >27 (60.0)</td><td align="center" valign="middle" >17 (51.5)</td><td align="center" valign="middle"  rowspan="2"  >0.557</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.455</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >18 (40.0)</td><td align="center" valign="middle" >16 (46.5)</td></tr><tr><td align="center" valign="middle" >胃腺癌分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >高分化</td><td align="center" valign="middle" >1 (2.8)</td><td align="center" valign="middle" >1 (3.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >中分化</td><td align="center" valign="middle" >21 (58.3)</td><td align="center" valign="middle" >12 (42.9)</td><td align="center" valign="middle" >1.754</td><td align="center" valign="middle"  colspan="2"  >0.479</td></tr><tr><td align="center" valign="middle" >低分化</td><td align="center" valign="middle" >14 (38.9)</td><td align="center" valign="middle" >15 (53.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >浸润深度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >黏膜层</td><td align="center" valign="middle" >8 (24.2)</td><td align="center" valign="middle" >4 (8.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >黏膜下层</td><td align="center" valign="middle" >17 (51.5)</td><td align="center" valign="middle" >14 (31.1)</td><td align="center" valign="middle"  rowspan="2"  >0.781</td><td align="center" valign="middle"  rowspan="2"  >0.854</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肌层</td><td align="center" valign="middle" >13 (39.4)</td><td align="center" valign="middle" >11 (24.4)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >浆膜层</td><td align="center" valign="middle" >7 (21.2)</td><td align="center" valign="middle" >4 (8.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >临床分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I期</td><td align="center" valign="middle" >12 (26.7)</td><td align="center" valign="middle" >12 (36.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >II期</td><td align="center" valign="middle" >18 (40.0)</td><td align="center" valign="middle" >8 (24.2)</td><td align="center" valign="middle"  rowspan="2"  >2.647</td><td align="center" valign="middle"  rowspan="2"  >0.453</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >11 (24.4)</td><td align="center" valign="middle" >8 (24.2)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >4 (8.9)</td><td align="center" valign="middle" >5 (15.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 胃癌组织中Hp感染情况与临床病理参数关系</p></sec><sec id="s7_2"><title>3.2. 胃癌组织中EBV、Hp感染情况及其与相关蛋白表达的情况</title><p>采用Mann-whitney U检验方法，结果提示EBVaGC中与EBVnGC中HER2、P53、Ki-67等蛋白表达差异均无统计学意义(U值分别为U = 0.110，U = 1.825，U = 0.426，P &gt; 0.05)；Hp阳性组与Hp阴性组HER2蛋白表达差异无统计学意义(U = 531.000, P &gt; 0.05)；Hp阳性组P53 (U = 369.500, P = 0.000)、Ki-67 (U = 386.000, P = 0.000)与Hp阴性组蛋白表达差异有统计学意义，见表3、表4、表5。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Analysis of EBV, Hp infections and expression of HER2 in Gastric Cancer Tissue</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >HER2表达</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  rowspan="2"  >U值</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >-</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >++</td><td align="center" valign="middle" >+++</td></tr><tr><td align="center" valign="middle" >EBV</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >0.110</td><td align="center" valign="middle"  rowspan="3"  >0.938</td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Hp</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >531.000</td><td align="center" valign="middle"  rowspan="3"  >0.560</td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><p>表3. EBV、Hp的感染情况与胃癌组织中HER2表达情况分析</p><p>注：-：阴性，+：弱阳性，++：阳性，+++：强阳性。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Analysis of EBV, Hp infections and expression of P53 in Gastric Cancer Tissue</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >P53表达</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  rowspan="2"  >U值</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >-</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >++</td><td align="center" valign="middle" >+++</td></tr><tr><td align="center" valign="middle" >EBV</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >1.825</td><td align="center" valign="middle"  rowspan="3"  >0.177</td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >13</td></tr><tr><td align="center" valign="middle" >Hp</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  rowspan="3"  >369.500</td><td align="center" valign="middle"  rowspan="3"  >0.000</td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >13</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td></tr></tbody></table></table-wrap><p>表4. EBV、Hp的感染情况与胃癌组织中P53表达情况分析</p><p>注：-：阴性，+：弱阳性，++：阳性，+++：强阳性。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Analysis of EBV, Hp infections and expression of Ki67 in Gastric Cancer Tissue</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >Ki67表达</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  rowspan="2"  >U值</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >-</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >++</td><td align="center" valign="middle" >+++</td></tr><tr><td align="center" valign="middle" >EBV</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >4</td><td align="center" valign="middle"  rowspan="2"  >0.426</td><td align="center" valign="middle"  rowspan="2"  >0.514</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >21</td></tr><tr><td align="center" valign="middle" >Hp</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >21</td><td align="center" valign="middle"  rowspan="2"  >386.000</td><td align="center" valign="middle"  rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4</td></tr></tbody></table></table-wrap><p>表5. EBV、Hp的感染情况与胃癌组织中Ki67表达情况分析</p><p>注：-：阴性，+：弱阳性，++：阳性，+++：强阳性。</p></sec><sec id="s7_3"><title>3.3. EBV/Hp感染与两者联合感染情况及其与P53、Ki-67蛋白表达的相关分析</title><p>通过Kruskal-Wallis H统计学方法检验EBV、Hp单独感染阳性组与两者联合感染中P53表达情况，两组P53、Ki-67表达均无显著差异，见表6。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> The infection of EBV/Hp and the co-infection with the comparison between the two groups in expression of P53 and Ki-6</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >P53表达</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  rowspan="2"  >P值</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >Ki-67表达</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >-</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >++</td><td align="center" valign="middle" >+++</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >++</td><td align="center" valign="middle" >+++</td></tr><tr><td align="center" valign="middle" >EBV阳性</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1.000<sup>*</sup></td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.000<sup>*</sup></td></tr><tr><td align="center" valign="middle" >Hp阳性</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >1.000<sup>#</sup></td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >1.000<sup>#</sup></td></tr><tr><td align="center" valign="middle" >均无感染</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.00<sup>&amp;</sup></td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.280<sup>&amp;</sup></td></tr><tr><td align="center" valign="middle" >联合感染</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表6. EBV/Hp的感染情况与两者联合感染情况及其与P53、Ki-67表达情况组间比较</p><p>注：-：阴性，+：弱阳性，++：阳性，+++：强阳性；*：EBV阳性组与联合感染P值，#：Hp阳性组与联合感染组P值，&amp;：EBV以及Hp两个均无感染与两者联合感染组P值。</p></sec><sec id="s7_4"><title>3.4. EBV、Hp二者一致性分析</title><p>采用Kappa一致性统计学方法检测EBV、Hp在胃癌组织中感染的一致性，结果显示胃癌组织中EBV、Hp二者不存在感染一致性(Kappa = −0.127, P = 0.058)。提示胃癌组织中EBV感染与Hp感染之间无相互影响，二者感染不存在一致性。见表7。</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> The Consistency analysis between EBV infection and Hp infections in Gastric Cancer Tissue</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Hp</th><th align="center" valign="middle"  colspan="2"  >EBV</th><th align="center" valign="middle"  rowspan="2"  >合计</th><th align="center" valign="middle"  rowspan="2"  >Kappa值</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >阴性</td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >45</td><td align="center" valign="middle"  rowspan="3"  >−0.127</td><td align="center" valign="middle"  rowspan="3"  >0.058</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >33</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >78</td></tr></tbody></table></table-wrap><p>表7. 胃癌组织中EBV与Hp一致性分析</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>EBV属于疱疹病毒γ亚科，其基因组为dsDNA，长度为172 kbp，可至少编码100余种病毒蛋白。2014年，癌症基因组计划(TCGA)项目团队在Nature期刊上报道了一项关于胃癌分子分型的研究，EBV 感染型、染色体不稳定型、微卫星不稳定型、基因组稳定型；将胃癌进行分子分型，有利于胃癌患者进行个体化的精准治疗，比如利于患者进行分子靶向治疗。EBV + 型胃癌在全球范围内的阳性率存在较大的差异，发生率约为2%~20%，平均约为10% [<xref ref-type="bibr" rid="hanspub.41823-ref3">3</xref>]。有研究显示，在正常癌旁胃上皮细胞以及胃癌浸润的淋巴组织细胞中EBERs检测为阴性，提示EBV在胃癌的发生发展中有一定的作用。因此，利用EBV通过与核糖核蛋白相结合从而可稳定与细胞核中的特性，以此可确定EBV临床感染。原位杂交技术检测EBER存在被认为是诊断EBV感染的金标准 [<xref ref-type="bibr" rid="hanspub.41823-ref4">4</xref>]。本研究应用原位杂交方法检测出EBV阳性率为12.8% (10/78)，与国外文献报道胃癌组织中EBV感染率相符。本研究显示EBV感染情况与患者性别、年龄、淋巴结有无转移、胃腺癌分化程度、浸润深度、临床分期中尚无统计学意义。这与国外的研究基本相符 [<xref ref-type="bibr" rid="hanspub.41823-ref5">5</xref>]。</p><p>幽门螺杆菌可致胃部产生炎症、破坏胃黏膜组织、影响胃酸产生，是大部分胃炎、胃十二指肠溃疡的病因，与胃黏膜相关B细胞淋巴瘤密切相关。有关文献报道，在胃癌患者中，Hp感染者约17.5%~86.2% [<xref ref-type="bibr" rid="hanspub.41823-ref6">6</xref>]。目前检测胃癌组织中Hp感染的方法有特殊染色美兰法、中性红染色法、苏木素-伊红染色法、尿素14C呼气试验以及免疫组织化学检测方法。我国有文献报道，免疫组织化学方法检测胃部组织Hp感染具有不受患者服用药物、胃部分切除术、胃黏膜出血等影响，具有切片易长期保存的优点，且敏感性、准确性、特异性高，以及有良好的对比度 [<xref ref-type="bibr" rid="hanspub.41823-ref7">7</xref>]，故Hp的免疫组织化学检测被认为是金标准。本研究采用免疫组织化学检测方法检测胃癌组织中Hp感染情况，结果显示Hp的阳性率为57.7% (45/78)，与文献报道基本相符。本研究发现胃癌组织中Hp感染与患者性别、年龄、淋巴结有无转移、胃腺癌分化程度、浸润深度、临床分期中尚无明显联系，与国外研究结果相一致 [<xref ref-type="bibr" rid="hanspub.41823-ref8">8</xref>]。近年国外有研究将胃癌组织中EBV感染与Hp感染联系起来进行分析两者对胃癌的生成、发展的作用 [<xref ref-type="bibr" rid="hanspub.41823-ref9">9</xref>]，并有研究表明，胃癌组织中EBV、Hp感染会促进胃癌组织中相关肿瘤蛋白表达。</p><p>人表皮生长因子受体2(HER2)是位于17q21的癌基因，编码一种分子质量185000的跨膜糖蛋白，隶属于ErbB－受体家族中的，且具有酪氨酸激酶活性。EB病毒相关胃癌中EBV约半数表达潜伏性膜蛋白2A (latent membrane protein 2A, LMP2A)。LMP2A是一种由497个氨基酸组成的蛋白，LMP2A通过诱导抑制ERK信号通路的激活从而降低细胞抗失巢凋亡。Iwakiri等 [<xref ref-type="bibr" rid="hanspub.41823-ref10">10</xref>] 研究表明EB病毒阳性的上皮细胞有活化的细胞外信号调节激酶通路(ERK)。这些研究结果表明EB病毒感染的相关上皮恶性肿瘤发生可能与LMP2A诱导ERK信号活化所致。Zhang等 [<xref ref-type="bibr" rid="hanspub.41823-ref11">11</xref>] 收集了78例EBVaGC、216例EBVnGC胃癌组织，采用免疫组织化学方法检测HER2，发现了HER2在EBVaGC表达显著降低，这表明可能由LMP2A引起HER2表达降低。本研究通过采用Mann-whitney U检验方法分析得出胃癌组织中EBV感染情况与胃癌组织中HER2表达无显著差异，这与国外文献有一定的差异，主要考虑本研究中总样本量较少，实验误差大，可采用扩大样本量的方法再次研究。</p><p>人类P53基因定位在17号染色体短臂上，它编码的蛋白质的分子量为43.7KDa，P53是一个转录序列，有维持基因组稳定的作用。EBV阳性胃癌中的分子特征包括PD-L1/2过表达、PIK3CA、ARID1A以及P53突变等，上述分子特征中P53突变是胃癌中基因改变事情最为普遍的一种，P53突变可导致P53蛋白表达上调。EBV阳性胃癌中，EBV早期复制需要P53的野生型参与，而病毒复制中晚期又可被病毒产物降解，从而使野生型P53失去抑癌作用，因此促进肿瘤的发生 [<xref ref-type="bibr" rid="hanspub.41823-ref12">12</xref>]。Ishii等 [<xref ref-type="bibr" rid="hanspub.41823-ref13">13</xref>] 研究表明胃癌组织中EBV阳性和EBV阴性中P53检出率无统计学差异，但是EBV阳性组胃癌组织中P53过表达率低于EBV阴性组，提示胃癌组织中EBV感染与P53表达异常有关。本组实验中，采用Mann-whirney U检验统计学方法比较胃癌组织中EBVaGC与EBVnGC P53表达情况，结果提示不论胃癌组织是否感染EBV与胃癌组织中P53表达无显著差异。EBVaGC组织中EBV感染与P53表达的相关性需进一步深入探讨研究。</p><p>Ki-67是一种细胞增殖核抗原蛋白，Ki-67除了不在G0期表达，在G1、S、G2、M期均有表达，其中在M期可达到最高峰，随着细胞有丝分裂结束，Ki-67随后降解，因此并提出与细胞有丝分裂整个过程密切相关，且Ki-67与肿瘤的发生发展有关，可以反映细胞的增殖活动。国外有研究者将EBV阳性胃癌组织中与EBV阴性胃癌组织中Ki-67蛋白表达进行研究分析，结果提示EBV阳性胃癌中的细胞增殖指数明显低于EBV阴性胃癌 [<xref ref-type="bibr" rid="hanspub.41823-ref15">15</xref>]。另有研究表明在EBER阳性淋巴上皮瘤样胃癌中细胞增殖指数值低于阴性的胃癌，提示EBVaGC中细胞增殖活性较EBVnGC细胞增殖活性低，这与相关文献提示EBVaGC的预后较好有关。本实验通过研究EBV阳性胃癌组织中与EBV阴性胃癌组织中Ki-67的表达情况，采用Mann-whirney U检验统计学方法进行检验，结果提示胃癌组织中EBV感染情况与Ki-67蛋白表达情况差异无统计学意义，与上述研究有所出入，此差异无统计学意义。</p><p>我国有研究发现胃癌组织中Hp感染情况与胃癌组织中HER2表达无相关性，HER2蛋白阳性表达情况与患者年龄、性别、临床分期及肿瘤发生部位也无相关性 [<xref ref-type="bibr" rid="hanspub.41823-ref14">14</xref>]。本实验采用免疫组织化学检测胃癌组织中Hp感染情况及HER2表达情况，采用Mann-whirney U检验统计学方法进行检验，结果显示胃癌组织中Hp感染情况与HER2蛋白表达情况差异无统计学意义，且HER2表达与患者性别、年龄、淋巴结转移、浸润深度、腺癌分化程度、肿瘤临床分期无相关性，与上述研究相近。但也有研究表明 [<xref ref-type="bibr" rid="hanspub.41823-ref15">15</xref>]，胃癌组织中Hp感染与胃癌的发生发展密切相关，而且Hp感染阳性情况与HER2蛋白的表达率有一定程度的促进效果。</p><p>有关文献报道 [<xref ref-type="bibr" rid="hanspub.41823-ref16">16</xref>]，P53、NF-κB、IL-1β的表达与胃癌组织中的Hp感染有正相关性，且均参与胃癌的发生与发展，推测可能是胃癌组织中Hp感染导致胃部炎性反应和抑癌基因失活，最后形成胃癌。我国有文献报道称 [<xref ref-type="bibr" rid="hanspub.41823-ref17">17</xref>]，P53在胃癌组织中表达阳性率在Hp阳性组高于阴性组，且胃癌组织中P53表达与Hp感染呈正相关，推测可能机制是胃癌组织中Hp感染使胃黏膜上皮细胞野生型的P53基因突变，从而使得P53表达上调，进而参与胃癌的发生发展。本实验采用免疫组织化学检测胃癌组织中Hp感染情况及P53表达情况，采用Mann-whirney U检验统计学方法进行检验，结果提示胃癌组织中Hp感染情况与P53蛋白表达情况有显著性差异，进一步进行胃癌组织中Hp阳性组与Hp阴性组两组之间的P53表达情况的Spearman相关性分析，结果提示胃癌组织中Hp感染情况与P53蛋白表达情况有相关性(r<sub>s</sub> = 0.477, P = 0.00)，且与Hp感染呈正相关(r<sub>s</sub> = 0.477)，P53表达情况与患者性别、年龄、有无淋巴结转移、浸润深度、腺癌分化程度及临床分期无显著差异。与上述文献报道基本相符。</p><p>有不同的研究报道关于组织中Hp对细胞增殖的作用，一部分体外试验提示Hp是抑制细胞增殖的因素 [<xref ref-type="bibr" rid="hanspub.41823-ref18">18</xref>]，但是相当一部分研究显示胃组织中Hp感染是胃上皮增生的促进因素。我国也有研究报道，随着胃癌形成的胃黏膜组织病变的加重，胃癌组织中Hp阳性组中的Ki-67表达显著上升 [<xref ref-type="bibr" rid="hanspub.41823-ref19">19</xref>]。我国近年有文献报道 [<xref ref-type="bibr" rid="hanspub.41823-ref20">20</xref>]，Hp阳性胃癌组Ki-67的表达高于Hp阴性胃癌组，表明Hp影响胃癌的发生发展的机制可能为促进细胞增殖和血管增生。本实验采用免疫组织化学检测胃癌组织中Hp感染情况及Ki-67表达情况，采用Mann-whirney U检验统计学方法进行检验，结果提示胃癌组织中Hp感染情况与Ki-67蛋白表达情况有显著性差异，进一步进行胃癌组织中Hp阳性组与Hp阴性组两组之间的P53表达情况的Spearman相关性分析，结果提示胃癌组织中Hp感染情况与P53蛋白表达情况有相关性(r<sub>s</sub> = 0.415, P = 0.00)，且与Hp感染呈正相关(r<sub>s</sub> = 0.415)，且胃癌组织中Ki-67表达情况与患者性别、年龄、有无淋巴结转移、浸润深度、腺癌分化程度及临床分期无相关性。与上述文献报道基本相符。胃癌组织中Ki-67表达与Hp感染呈正相关，考虑与胃癌组织中Hp促进胃上皮增生有关。</p><p>目前胃癌组织中EBV感染联合Hp感染对胃癌组织中的相关蛋白表达的影响的研究较少。国外有关文献报道提示，胃癌组织中同时感染EBV及Hp可以诱导比单独感染EBV或者Hp更严重的炎症反应，使得胃癌的风险增加。有研究表明 [<xref ref-type="bibr" rid="hanspub.41823-ref21">21</xref>]，EBV、Hp二者的共同的诱导途径可通过TCF-4、β-catenin信号传导通路激活胃上皮转化因子，从而改变胃上皮细胞在胃癌的发生发展中的作用。此外EBV和Hp感染的胃癌组织中B淋巴细胞瘤-2基因(B-cell lymphoma-2, bcl2)的表达升高，这提示着胃癌组织中Bcl2过度表达可能是两者合并感染的结果之一。已有很多报道称EBV感染可引起广泛甲基化，且慢性胃炎中的Hp感染可诱导胃上皮甲基化可能参与胃癌的发生发展。以上研究均提示胃癌组织中EBV、Hp二者同时感染有相互影响。但国外也有研究表明EBV虽然与Hp有导致胃部炎症形成的共同毒力因子，且有临床证据表明胃部组织中EBV活动可以和Hp共同促进上皮细胞炎症发生，但是两者之间无相关性 [<xref ref-type="bibr" rid="hanspub.41823-ref22">22</xref>]。我国有文献报道，胃癌组织中EBV感染和Hp感染的阳性率之间无相关性，EBV与Hp感染可能是胃癌发生发展中的两个独立因素 [<xref ref-type="bibr" rid="hanspub.41823-ref23">23</xref>]。本研究将胃癌组织中EBV或Hp感染组与两者联合感染组与P53及Ki-67蛋白表达程度的差异性用Kruskal-Wallis秩和检验进行组间比较，结果提示EBV、Hp单独感染组与两者联合感染组P53 (P = 1.000)、Ki-67 (P = 1.000)蛋白表达的影响无显著差异。进一步将胃癌组织中EBV感染情况与Hp感染情况进行一致性分析，结果发现两者之间不存在感染一致性(Kappa = −0.127, P = 0.058)。本次实验结果提示胃癌组织中EBV、Hp二者联合感染对相关蛋白的表达无显著影响，胃癌组织中EBV、Hp感染可能为胃癌发生发展的独立因素。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，胃癌组织中EBV感染对HER2、P53、Ki-67蛋白表达的影响无相关性。胃癌组织中Hp感染情况与P53、Ki-67的表达呈正相关，但是根据现有文献报道胃癌组织中Hp感染情况与胃癌组织中HER2表达情况的相关性各有不同，要进一步了解胃癌组织中Hp感染情况与HER2表达有无相关性、是促进HER2表达还是抑制HER2表达，需进一步扩大样本量，排除影响因素，从而进一步探究。本研究结果提示胃癌组织中EBV、Hp两者感染无相关性，且两者联合感染对P53、Ki63蛋白表达无增强作用。EBV在胃癌发生中的确切作用仍未完全了解，需要进一步研究证实EBV与Hp感染之间的相互作用。考虑本研究样本量小，EBV阳性病例少，可扩大研究的样本量进一步探讨。</p></sec><sec id="s10"><title>基金项目</title><p>南华大学研究生创新科研项目(203YXC031)。</p></sec><sec id="s11"><title>文章引用</title><p>江 杨,唐艳芳,张雪纯,邱荣元,王 婕,毛 敏,刘崇梅. 胃癌组织中EBV、Hp感染及其与HER2、P53、Ki-67蛋白表达的相关性研究EBV and HP Infections in Gastric Cancer Tissues and Their Correlation with HER2, P53, Ki-67 Gene Expression[J]. 世界肿瘤研究, 2021, 11(02): 48-58. https://doi.org/10.12677/WJCR.2021.112007</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41823-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Torre, L.A., Bray, F., Siegel, R.L., et al. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108. https://doi.org/10.3322/caac.21262</mixed-citation></ref><ref id="hanspub.41823-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Li, T., Guo, H., Zhao, X., et al. (2016) Gastric Cancer Cell Proliferation and Survival Is Enabled by a Cyclophilin B/STAT3/miR-520d-5p Signaling Feedback Loop. Cancer Research, 77, 1225.  
https://doi.org/10.1158/0008-5472.CAN-16-0357</mixed-citation></ref><ref id="hanspub.41823-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W., Zheng, R., Zhang, S., et al. (2014) Annual Report Status of Cancer in China, 2010. Chinese Journal of Cancer Research, 26, 48-58. https://doi.org/10.1007/BF02997493</mixed-citation></ref><ref id="hanspub.41823-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Andal, N., Shanthi, P., Krishnan, K.B., et al. (2003) The Epstein Barr Virus and Gastric Carcinoma. Indian Journal of Pathology &amp; Microbiology, 46, 34-36.</mixed-citation></ref><ref id="hanspub.41823-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Camargo, M.C., Kim, W.H., Chiaravalli, A.M., et al. (2014) Improved Survival of Gastric Cancer with Tumour Epstein-Barr Virus Positivity: An International Pooled Analysis. Gut, 63, 236-243.  
https://doi.org/10.1136/gutjnl-2013-304531</mixed-citation></ref><ref id="hanspub.41823-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wang, F., Sun, G., Zou, Y., et al. (2013) Protective Role of Helicobacter pylori Infection in Prognosis of Gastric Cancer: Evidence from 2454 Patients with Gastric Cancer. PLoS ONE, 8, 62440-62447.  
https://doi.org/10.1371/journal.pone.0062440</mixed-citation></ref><ref id="hanspub.41823-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">吴赛青, 欧阳劲光, 窦红漫, 等. 三种胃幽门螺杆菌检测方法比较[J]. 临床与实验病理学杂志, 2019, 35(4): 486-487.</mixed-citation></ref><ref id="hanspub.41823-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">De Souza, C.R., de Oliveira, K.S., Ferraz, J.J., et al. (2014) Occurrence of Helicobacter pylori and Epstein Barr Virus Infection in Endoscopic and Gastric Cancer Patients from Northern Brazil. BMC Gastroenterology, 14, 179-183.  
https://doi.org/10.1186/1471-230X-14-179</mixed-citation></ref><ref id="hanspub.41823-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Tsao, S.W., Tsang, C.M., Pang, P.S., et al. (2012) Te Biology of EBV Infection in Human Epithelial Cells. Seminars in Cancer Biology, 22, 137-143. https://doi.org/10.1016/j.semcancer.2012.02.004</mixed-citation></ref><ref id="hanspub.41823-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Iwakiri, D., Minamitani, T. and Samanta, M. (2013) Epstein-Barr Virus Latent Membrane Protein 2A Contributes to Anoikis Resistance through ERK Activation. Journal of Virology, 87, 8227-8234.  
https://doi.org/10.1128/JVI.01089-13</mixed-citation></ref><ref id="hanspub.41823-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y.W., Zhao, X.X., Tan, C., et al. (2014) Epstein-Barr Virus Latent Membrane Protein 2A Suppresses the Expression of HER2 via a Pathway Involving TWIST and YB-1 in Epstein-Barr Virus-Associated Gastric Carcinomas. Oncotarget, 6, 207-220. https://doi.org/10.18632/oncotarget.2702</mixed-citation></ref><ref id="hanspub.41823-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">李北芳, 高静. EBV相关性胃癌罕见p53基因突变的可能机制与意义[J]. 中国肿瘤临床, 2017, 44(11): 522-526.</mixed-citation></ref><ref id="hanspub.41823-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ishii, H., Gobe, G., Kawakubo, Y., et al. (2001) Interrelationship between Eptein-Barr Virus Infection in Gastric Carcinomas and the Expression of Apoptosis-Associated Proteins. Histopathology, 38, 111-119. 
https://doi.org/10.3390/ijms130810176</mixed-citation></ref><ref id="hanspub.41823-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">王治兰, 贾淑娟, 陈俊红. 幽门螺杆菌感染与胃癌组织中HER2表达的相关性研究[J]. 中国现代医生, 2015, 53(24): 14-16.</mixed-citation></ref><ref id="hanspub.41823-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">杨勇, 赵子龙, 周国江. 幽门螺杆菌感染与胃癌组织中HER2表达的相关性研究[J]. 实用临床医药杂志, 2017, 21(23): 222-223.</mixed-citation></ref><ref id="hanspub.41823-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">魏茜, 余树林, 黄宜峰. 胃癌组织中P53､IL-1β､NF-κB的表达及与幽门螺杆菌感染的相关性分析[J]. 中国中西医结合消化杂志, 2019, 27(3): 228-231.</mixed-citation></ref><ref id="hanspub.41823-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">王名法, 刘友斌. XPF､p53蛋白在胃癌组织中的表达及与幽门螺杆菌L型感染的关系[J]. 临床与实验病理学杂志, 2015, 31(10): 1089-1094.</mixed-citation></ref><ref id="hanspub.41823-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yu, X.W., Xu, Y., Gong, Y.H., et al. (2011) Helicobacter pylori Induces Malignant Transformation of Gastric Epithelial Cells in Vitro. APMIS, 119, 187-197. https://doi.org/10.1111/j.1600-0463.2010.02709.x</mixed-citation></ref><ref id="hanspub.41823-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">刘爱群, 葛莲英, 罗元, 等. 胃癌变过程中Hp感染与凋亡基因Bcl-2表达相关性研究[J]. 广西医学, 2011, 4(32): 444-446.</mixed-citation></ref><ref id="hanspub.41823-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">吴峰阶, 朱君, 赵大华, 等. 幽门螺杆菌感染与胃癌组织中Ki-67及EGFR表达的关系[J]. 临床普外科电子杂志, 2017, 5(3): 14-19.</mixed-citation></ref><ref id="hanspub.41823-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Szkaradkiewicz, A., Karpinski, T.M., Majewski, J., et al. (2015) Te Participation of p53 and bcl-2 Proteins in Gastric Carcinomas Associated with Helicobacter pylori and/or Epstein-Barr Virus (EBV). Polish Journal of Microbiology, 64, 211-216. https://doi.org/10.5604/01.3001.0009.2116</mixed-citation></ref><ref id="hanspub.41823-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Flores-Luna, L., Camorlinga-Ponce, M., Hernandez-Suarez, G., et al. (2012) The Utility of Serologic Tests as Biomarkers for Helicobacter pylori-Associated Precancerous Lesions and Gastric Cancer Varies between Latin American Countries. Cancer Causes Control, 24, 241-248. https://doi.org/10.1007/s10552-012-0106-8</mixed-citation></ref><ref id="hanspub.41823-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">杨艳丽, 胡建国, 司岑. EBV、Hp感染与胃癌的关系及相互作用研究[J]. 天津医药, 2013, 41(11): 1048-1051.</mixed-citation></ref></ref-list></back></article>